New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients "Seeing these promising results validates our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback